Certain Common Shares of Apogee Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 10-JAN-2024. These Common Shares will be under lockup for 181 days starting from 13-JUL-2023 to 10-JAN-2024.

Details:
The Company and its directors and executive officers and the holders of substantially all of common stock and securities exercisable for or convertible into common stock outstanding immediately upon the closing of this offering (including shares of our non-voting common stock), have agreed with the underwriters that, until 180 days after the date of the underwriting agreement related to this offering, company and its officers will not, without the prior written consent of Jefferies LLC and Cowen and Company, LLC, directly or indirectly, offer, sell, contract to sell, pledge, grant any option to purchase, lend or otherwise transfer or dispose of any shares of common stock, or any options or warrants to purchase any shares of common stock, or any securities convertible into, exchangeable for or exercisable or that represent the right to receive shares of common stock, or engage in any hedging or other transaction or arrangement which is designed to or which reasonably could be expected to lead to or result in a sale, loan, pledge or other disposition, or transfer any of the economic consequences of ownership, in whole or in part, directly or indirectly, of the securities, whether any such transaction or arrangement would be settled by delivery of common stock or other securities, in cash or otherwise. These agreements are described in the section titled ?Underwriting.? Jefferies LLC and Cowen and Company, LLC, in their sole discretion, and at any time or from time to time before the termination of the 180-day period release any of the securities subject to these lock-up agreements.